Key result
NOACs show no greater risk than VKAs during invasive dental procedures, making suspension unnecessary.
Why the study?
Do new oral anticoagulants pose greater risks than conventional oral anticoagulants during invasive dental treatment?
Do new oral anticoagulants pose greater risks than conventional oral anticoagulants during invasive dental treatment?
New oral anticoagulants do not require routine suspension prior to invasive dental procedures, similar to conventional vitamin K antagonists.
Answers are grounded in this paper and cite their sources.
Supports continuing NOACs without routine suspension for invasive dental procedures; confirms safety equivalence to conventional agents in Level 1 evidence.
INTRODUCTION: For over 50 years, vitamin K antagonists such as warfarin (Aldocumar®) and acenocoumarol (Sintrom®) have been the gold standard for reducing the risk of cerebrovascular events. In the last 5 years alternative anticoagulants have been evaluated that act directly upon a concrete target within the coagulation cascade, thereby affording a more predictable anticoagulant effect. The present study offers an update on the new oral anticoagulants and reviews the implications referred to the dental care of patients administered these substances. MATERIAL AND METHODS: An exhaustive PubMed-Medline and Cochrane Library search was made of the main alternatives to conventional oral anticoagulation, covering those studies published in English and Spanish over the last 10 years. Specialized textbooks and pharmaceutical catalogs were also consulted. A total of 184 articles were identified, of which 76 met the inclusion criteria. RESULTS: The new oral anticoagulants dabigatran, rivaroxaban and apixaban are safe and effective, and offer a series of advantages, including rapid action, no need for constant monitoring, few drug and food interactions, and a broad therapeutic margin. These drugs are expensive, however, and some lack a specific antidote, while others must be administered twice a day. Regarding the dental treatment of patients receiving these drugs, suspension or modification of the background medication is not required when performing invasive dental procedures, except where indicated by the prescribing physician. CONCLUSIONS: The new oral anticoagulants do not pose significantly greater risks than conventional oral anticoagulants when providing invasive dental treatment, and their suspension is not strictly required in such situations.
No takes yet. Share an insight, caveat, or question.
Mingarro-de-Leon et al. (2013) conducted a review in Patients receiving oral anticoagulants requiring dental care. New oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Vitamin K antagonists was evaluated. New oral anticoagulants do not pose significantly greater risks than conventional oral anticoagulants during invasive dental treatment, and their suspension is not strictly required.
Synapse has enriched 10 related papers. Consider them for comparative context: